Akums Drugs and Pharmaceuticals Ltd. has announced robust financial results for the first quarter of FY27, ending June 30, 2026. The company reported a 13.9% year-on-year increase in revenue, reaching ₹1,167 crore. Profit after tax (PAT) also saw significant growth, rising to ₹101 crore from ₹65 crore in the prior year’s corresponding quarter. The strong performance was primarily fueled by its Contract Development and Manufacturing Organization (CDMO) business.
Akums Reports Strong Q1 FY27 Performance
Akums Drugs and Pharmaceuticals Ltd., a leading Contract Development and Manufacturing Organization (CDMO), has reported a strong start to the fiscal year 2027. For the quarter ended June 30, 2026, the company announced consolidated financial results highlighting significant year-on-year growth in key financial metrics.
Financial Highlights
The company’s operating revenue for Q1 FY27 stood at ₹1,167 crore, marking a substantial 13.9% increase compared to ₹1,024 crore in Q1 FY26. EBITDA also demonstrated robust growth, increasing by 35.4% to ₹175 crore, with the EBITDA margin improving to 15.0% from 12.6% in the same period last year. Profit After Tax (PAT) for the quarter was ₹101 crore, a significant rise from ₹65 crore in Q1 FY26, leading to an improved PAT margin of 8.4% from 6.2%.
CDMO Business Drives Growth
The CDMO segment was identified as the primary driver of this growth. CDMO revenue increased to ₹964 crore, up from ₹813 crore in Q1 FY26. The segment’s EBITDA grew by 36.8% year-on-year to ₹163 crore. This performance is attributed to continued volume growth and favorable improvements in API prices.
Management Commentary
Commenting on the results, Mr. Sanjeev Jain, Managing Director, stated, “FY27 has begun on a strong and encouraging note. The consistent performance of CDMO showcases healthy demand environment as well as our clients’ trust in Akums as the preferred manufacturing partner.”
Mr. Sandeep Jain, Managing Director, added, “We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable growth in the years ahead.”
Extract of Consolidated Financial Results (Rs Cr)
| Particulars | Q1 FY 27 | Q4 FY 26 | Q1 FY 26 |
| Revenue | 1,167 | 1,158 | 1,024 |
| Cost of goods sold | 645 | 660 | 582 |
| Employee Cost | 201 | 199 | 176 |
| Other Expenses | 145 | 147 | 137 |
| EBITDA | 175 | 152 | 129 |
| EBITDA Margin | 15.0% | 13.1% | 12.6% |
| PAT | 101 | 81 | 65 |
| PAT Margin | 8.4% | 6.8% | 6.2% |
Source: BSE
